CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial is studying the side effects and best dose of CCI-779 and bevacizumab
and to see how well they work in treating patients with metastatic or unresectable kidney
cancer. Drugs used in chemotherapy, such as CCI-779, work in different ways to stop the
growth of tumor cells, either by killing the cells or by stopping them from dividing.
Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some
find tumor cells and kill them or carry tumor-killing substances to them. Others interfere
with the ability of tumor cells to grow and spread. Bevacizumab may also stop the growth of
kidney cancer by blocking blood flow to the tumor. Giving CCI-779 together with bevacizumab
may kill more tumor cells.